Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Routine prenatal care.

BIBLIOGRAPHIC SOURCE(S)

  • Institute for Clinical Systems Improvement (ICSI). Routine prenatal care. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Aug. 87 p. [260 references]

GUIDELINE STATUS

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

Note from the National Guideline Clearinghouse (NGC) and the Institute for Clinical systems Improvement (ICSI): For a description of what has changed since the previous version of this guidance, refer to Summary of Changes Report - August 2007.

The recommendations for routine prenatal care are presented in the form of a table with accompanying annotations. Clinical highlights and a table for routine prenatal care follow. The reader is directed to the original guideline document for further discussion of each of the following topics.

Clinical Highlights

  • Identify patients with greater potential for high-risk for pregnancy and provide appropriate preconception counseling (Annotation #4 -- see original guideline document)
  • Each pregnant patient should receive visit-specific screening tests, education, immunizations, and chemoprophylaxis as described on the prenatal care table.
  • Each pregnant patient and each patient planning a pregnancy should receive a comprehensive risk assessment and appropriate risk-related interventions, including risks for preterm labor, relevant infectious diseases, and relevant genetic disorders (Annotations #2, 4 -- see the original guideline document).
  • For patients with previous Cesarean section, provide education of risks and benefits associated with vaginal birth after Cesarean (VBAC). Assess and document patients' desire and appropriateness for VBAC (Annotation #21 -- see original guideline document).
  • Counseling for appropriate aneuploidy testing (screening) should be offered to all pregnant women regarding the different screening options and the limitations and benefits of each of the screening and diagnostic tests (Annotation #23 – see original guideline document)
Event Preconception Visit Visit 1**
6–8 weeks
Visit 2
10–12 weeks
Visit 3
16–18 weeks
Visit 4
22 weeks
Screening Maneuvers Risk profiles

Height and weight/BMI

Blood pressure

History and physical

Cholesterol and HDL

Cervical cancer screening

Rubella/rubeola

Varicella

Domestic abuse
Risk profiles

GC/Chlamydia

Height and weight/BMI

Blood pressure

History and physical*

Rubella

Varicella

Domestic abuse

Hemoglobin

ABO/Rh/Ab

Syphilis

Urine culture*

HIV

[Blood lead screening]

[VBAC]

Hepatitis B surface Ag
Weight

Blood pressure

Fetal heart tones

Fetal aneuploidy screening
Weight

Blood pressure

Fetal heart tones

Fetal aneuploidy screening

OB ultrasound (optional)

Fundal height

[Cervical assessment]
Weight

Blood pressure

Fetal heart tones

Fundal height

[Cervical assessment]
Counseling
Education
Intervention
PTL education and prevention

Substance use

Nutrition and weight

Domestic abuse

List of medications, herbal supplements, and vitamins

Accurate recording of menstrual dates
PTL education and prevention

Prenatal and lifestyle education
  • Physical activity
  • Nutrition
  • Follow-up of modifiable risk factors
  • Warning signs
  • Course of care
  • Physiology of pregnancy
Discuss fetal aneuploidy screening
PTL education and prevention

Prenatal and lifestyle education
  • Fetal growth
  • Review lab results from visit 1
  • Breast-feeding
  • Physiology of pregnancy
  • Follow-up of modifiable risk factors
PTL education and prevention

Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Physiology of pregnancy
  • Second trimester growth
  • Quickening
PTL education and prevention

Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Classes
  • Family issues
  • Length of stay
  • GDM
  • [RhoGAM]
Immunization and Chemoprophylaxis Tetanus booster

Rubella/MMR

[Varicella/VZIG]

Hepatitis B vaccine

Folic acid supplement
Tetanus booster

Nutritional supplements

Influenza

[Varicella/VZIG]
  [Progesterone]  

 

Event Visit 5
28 weeks
Visit 6
32 weeks
Visit 7
36 weeks
Visit 8-11
38-41 weeks
Screening Maneuvers PTL risk

Weight

Blood pressure

Fetal heart tones

Fundal height

[Cervical assessment]

GDM

Domestic abuse

[Rh antibody status]

Hepatitis B surface Ag

[GC/Chlamydia]
Weight

Blood pressure

Fetal heart tones

Fundal height
Weight

Blood pressure

Fetal heart tones

Fundal height

Cervix exam

Confirm fetal position

Culture for group B streptococcus
Weight

Blood pressure

Fetal heart tones

Fundal height

Cervix exam
Counseling
Education
Intervention
PTL education and prevention

Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Work
  • Physiology of pregnancy
  • Preregistration
  • Fetal growth
Awareness of fetal movement
PTL education and prevention

Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Travel
  • Sexuality
  • Pediatric care
  • Episiotomy
Labor and delivery issues

Warning signs/ pregnancy-induced hypertension

[VBAC]
Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Postpartum care
  • Management of late pregnancy symptoms
  • Contraception
  • When to call provider
  • Discussion of postpartum depression
Prenatal and lifestyle education
  • Follow-up of modifiable risk factors
  • Postpartum vaccinations
  • Infant CPR
  • Post-term management
Labor and delivery update
Immunization and Chemoprophylaxis [ABO/Rh/Ab (RhoGAM)]      

[Bracketed] items refer to high risk groups only.

*It is acceptable for the history and physical and laboratory tests listed under Visit 1 to be deferred to Visit 2 with the agreement of both the patient and the provider.
** Should also include all subjects listed for the preconception visit if none occurred.

Abbreviations: ABO, BMI, body mass index; CPR, cardiopulmonary resuscitation; GC, gonococci; GDM, gestational diabetes mellitus; HDL, high density lipoprotein; HIV, human immunodeficiency virus; MMR, measles/mumps/rubella; OB, obstetrics; PTL, preterm labor; RhoGAM, Rho(D) immune globulin; VBAC, vaginal birth after Cesarean; VZIG, varicella zoster immune globulin

Practices to Consider Discontinuing

  • Pelvimetry
  • Routine urine dipsticks and routine urinalysis
  • Routine evaluation for edema
  • Routine testing for cytomegalovirus (CMV), parvovirus, toxoplasmosis
  • Routine nutritional supplements
  • Routine testing for bacterial vaginosis (may be necessary in women with a history of preterm labor)

CLINICAL ALGORITHM(S)

The following algorithms are provided in Appendix H of the original guideline document:

  • Aneuploidy Testing Integrated Screening Tool
  • Aneuploidy Testing Stepwise Sequential Screening Tool
  • Aneuploidy Testing Contingency Screening Tool

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Institute for Clinical Systems Improvement (ICSI). Routine prenatal care. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Aug. 87 p. [260 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1997 Aug (revised 2007 Aug)

GUIDELINE DEVELOPER(S)

Institute for Clinical Systems Improvement - Private Nonprofit Organization

GUIDELINE DEVELOPER COMMENT

Organizations participating in the Institute for Clinical Systems Improvement (ICSI): Affiliated Community Medical Centers, Allina Medical Clinic, Altru Health System, Aspen Medical Group, Avera Health, CentraCare, Columbia Park Medical Group, Community-University Health Care Center, Dakota Clinic, ENT Specialty Care, Fairview Health Services, Family HealthServices Minnesota, Family Practice Medical Center, Gateway Family Health Clinic, Gillette Children's Specialty Healthcare, Grand Itasca Clinic and Hospital, HealthEast Care System, HealthPartners Central Minnesota Clinics, HealthPartners Medical Group and Clinics, Hutchinson Area Health Care, Hutchinson Medical Center, Lakeview Clinic, Mayo Clinic, Mercy Hospital and Health Care Center, MeritCare, Mille Lacs Health System, Minnesota Gastroenterology, Montevideo Clinic, North Clinic, North Memorial Care System, North Suburban Family Physicians, Northwest Family Physicians, Olmsted Medical Center, Park Nicollet Health Services, Pilot City Health Center, Quello Clinic, Ridgeview Medical Center, River Falls Medical Clinic, Saint Mary's/Duluth Clinic Health System, St. Paul Heart Clinic, Sioux Valley Hospitals and Health System, Southside Community Health Services, Stillwater Medical Group, SuperiorHealth Medical Group, University of Minnesota Physicians, Winona Clinic, Ltd., Winona Health

ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; e-mail: icsi.info@icsi.org; Web site: www.icsi.org.

SOURCE(S) OF FUNDING

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

GUIDELINE COMMITTEE

Ob/Gyn Steering Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Dale Akkerman, MD (Work Group Leader) (Park Nicollet Health Services) (OB/GYN); Tamara Johnston, MD (Northwest Family Physicians) (Family Medicine); Katie Klingberg, MD (Northpoint Health and Wellness) (Family Medicine); Kari Rabie, MD (Southside Community Health Services) (Family Medicine); Jennifer Schriever, MD (Sioux Valley Hospitals and Health System) (Family Medicine); Carol Stark, MD (Family HealthServices Minnesota) (Family Medicine); Peter Van Eerden, MD (Sioux Valley Hospitals and Health System) (Maternal-Fetal Medicine); Georgeanne Croft, CNM (HealthPartners Medical Group) (Nurse Midwifery); Amy Knox, CNM (Park Nicollet Health Services) (Nurse Midwifery); John A. Jefferies, MD (Mayo Clinic) (OB/GYN); Joan Kreider, MD (HealthPartners Medical Group) (OB/GYN); John Vickers, MD (HealthPartners Medical Group) (OB/GYN); Corinne Esch, RN, CDS (HealthPartners Medical Group) (OB/GYN Nursing); Nancy Jaeckels (Institute for Clinical Systems Improvement) (Implementation Advisor); Linda Setterlund, MA (Institute for Clinical Systems Improvement) (Facilitator)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

GUIDELINE STATUS

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

GUIDELINE AVAILABILITY

Electronic copies of the updated guideline: Available from the Institute for Clinical Systems Improvement (ICSI) Web site.

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Appendices A – I of the original guideline document include risk assessment forms, prenatal worksheets, screening algorithms, and additional educational material.

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

PATIENT RESOURCES

The following is available:

  • Routine prenatal care. Bloomington (MN): Institute for Clinical Systems Improvement, 2007 Sept. 50 p.

Electronic copies: Available from the Institute for Clinical Systems Improvement (ICSI) Web site.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This summary was completed by ECRI on February 15, 2000. The information was verified by the guideline developer on March 15, 2000. This summary was updated by ECRI on April 19, 2001, May 7, 2002, February 5, 2003, March 25, 2004, November 12, 2004, and October 13, 2005. This summary was updated by ECRI on March 3, 2006 following the FDA advisory on varicella zoster immune globulin (VZIG). This summary was updated by ECRI on November 30, 2006. This NGC summary was updated by ECRI Institute on December 14, 2007.

COPYRIGHT STATEMENT

This NGC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Guideline) is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

The abstracted ICSI Guidelines contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Guidelines are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Guidelines are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Guidelines are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Guidelines.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo